ArticleInternational journal of hematology2025
Concomitant letermovir affects the optimal concentration-to-dose ratio of tacrolimus after switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving fluconazole prophylaxis.
Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Letermovir is often administered for cytomegalovirus prophylaxis after allogeneic hematopoietic cell transplantation (HCT). Concomitant use of letermovir and azole antifungals affects tacrolimus concentration. Therefore, in HCT recipients taking fluconazole, letermovir may affect the optimal tacrolimus conversion ratios when switching from continuous intravenous infusion to oral administration. In this study, we retrospectively evaluated tacrolimus conversion ratios in 104 HCT recipients taking fluconazole with and without concomitant letermovir. The median tacrolimus concentration-to-dose (C/D) ratios with and without letermovir were 18.2 and 20.6 (ng/mL)/(mg/day), respectively, before conversion from continuous infusion (C/Dciv) (p = 0.21) and 2.9 and 1.9 (ng/mL)/(mg/day), respectively, after conversion (p < 0.01). The median (C/Dpo)/(C/Dciv) ratios with and without letermovir were 0.15 and 0.10, respectively (p < 0.01). These results suggest that in HCT recipients taking fluconazole, the optimal conversion ratio when switching from continuous intravenous infusion to oral administration is 0.7-fold lower with concomitant letermovir than without it.
Indexed as
Identifiers
39928215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.